Related references
Note: Only part of the references are listed.Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease
L. Chouchana et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and-2 extension studies
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2012)
Guidelines for the management of inflammatory bowel disease in adults
Craig Mowat et al.
GUT (2011)
Optimization of conventional therapy in patients with IBD
Kirstin M. Taylor et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Glucocorticoid resistance in inflammatory diseases
Peter J. Barnes et al.
LANCET (2009)
European evidence-based Consensus on the management of ulcerative colitis: Current management
S. P. L. Travis et al.
JOURNAL OF CROHNS & COLITIS (2008)
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
E. F. Stange et al.
JOURNAL OF CROHNS & COLITIS (2008)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
Geert D'Haens et al.
GASTROENTEROLOGY (2007)
Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies
T. J. Creed et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression
Dan Turner et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
M Lémann et al.
GASTROENTEROLOGY (2006)
European evidence based consensus on the diagnosis and management of Crohn's disease:: current management
SPL Travis et al.
GUT (2006)
European evidence based consensus on the diagnosis and management of Crohn's disease:: definitions and diagnosis
EF Stange et al.
GUT (2006)
American Gastroenterological Association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
GR Lichtenstein et al.
GASTROENTEROLOGY (2006)
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations
R Caprilli et al.
GUT (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
WA Faubion et al.
GASTROENTEROLOGY (2001)
Share Paper
